grants_govRFA-NS-26-001
Open
Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Response deadline
- Nov 10, 2026 Due in 43 days
- Date posted
- May 4, 2026
- Source
- Open notice
Description
The purpose of this Notice of Funding Opportunity (NOFO) is to solicit applications for the conduct of scientific research utilizing data from expanded access (EA) for investigational drugs or biological products as described in section 561 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360bbb). These applications will target intermediate size populations of patients living with amyotrophic lateral sclerosis (ALS) who are not eligible for ongoing clinical trials for the prevention, diagnosis, mitigation, treatment, or cure of ALS.
Classifications
- NAICS93.853
Documents (1)
- DownloadRFA-NS-26-001-Full-Announcement.htmltext/html;charset=UTF-8138 KB
Contacts
Similar contracts
- NIH Brain Development Cohorts (NBDC) and Population Assessment of Tobacco and Health (PATH) Study Biospecimen Access (X01 Clinical Trial Not Allowed)Due Apr 17, 2029
- NINDS Efficacy and Exploratory Clinical Trials (UG3/UH3 - Clinical Trial Required)Due Mar 9, 2029
- Single Source: Post-Stroke Vascular Contributions to Cognitive Impairment and Dementia (VCID) in the United States (U19 - Clinical Trial Not Allowed)Due Sep 28, 2026
- NIH Small Business Innovation Research (SBIR) Phase IIB Strategic Breakthrough Award (Parent [R44] Clinical Trial Optional)Due Apr 5, 2029
- NINDS Child Neurology Career Development Program (CNCDP) (K12 - Clinical Trial Not Allowed)Due Jul 10, 2026
- Translational Efforts to Advance Gene-based Therapies for Ultra-Rare Neurological and Neuromuscular Disorders (U01 - Clinical Trial Optional)Due Oct 8, 2027